Close the acquisition of Five Prime Therapeutics
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 4 Mar 2021
- Due
- 30 Jun 2021
- Delivered
- 16 Apr 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The transaction is expected to close by the end of the second quarter”
What we found
Evidence strength A What the grades mean
Amgen completed the acquisition of Five Prime Therapeutics on April 16, 2021, which is before the deadline of June 30, 2021.
-
A Amgen Inc. 10-Q filed 2021-08-04
“On April 16, 2021, Amgen completed its acquisition of Five Prime Therapeutics, Inc. (Five Prime) for total consideration of $1.6 billion, net of cash acquired.” ✓ confirmed on the page
Market reaction: the shares moved -6.0% against the S&P 500 over the three sessions around the disclosure (3 Aug 2021 to 6 Aug 2021). What this measures
Checked 2 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Acquisition close
- Indicative materiality
- High rules
- Action
- Close
- Deliverable
- acquisition of Five Prime Therapeutics
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: subject to customary closing conditions; tender of at least a majority of the outstanding shares of Five Prime’s common stock; expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976
- Depends on
- Regulatory, Shareholder
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Late”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Amgen Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-AMGN-004067 · Corrections policy